 |
|
A Randomized Placebo-Controlled Trial of Fluoxetine in Body Dysmorphic Disorder
Katharine A. Phillips, MD;
Ralph S. Albertini, MD;
Steven A. Rasmussen, MD
Arch Gen Psychiatry. 2002;59:381-388.
Background Research on the pharmacotherapy of body dysmorphic disorder (BDD), a
common and often disabling disorder, is limited. Available data suggest that
this disorder may respond to serotonin reuptake inhibitors. However, no placebo-controlled
treatment studies of BDD have been published.
Methods Seventy-four patients with DSM-IV BDD or its
delusional variant were enrolled and 67 were randomized into a placebo-controlled
parallel-group study to evaluate the efficacy and safety of fluoxetine hydrochloride.
After 1 week of single-blind placebo treatment, patients were randomized to
receive 12 weeks of double-blind treatment with fluoxetine or placebo. Outcome
measures included the Yale-Brown Obsessive Compulsive Scale Modified for Body
Dysmorphic Disorder (BDD-YBOCS) (the primary outcome measure), the Clinical
Global Impressions Scale, the Brown Assessment of Beliefs Scale, and other
measures.
Results Results of the BDD-YBOCS indicated that fluoxetine was significantly
more effective than placebo for BDD beginning at week 8 and continuing at
weeks 10 and 12 (F1,64 = 16.5; P<.001).
The response rate was 18 (53%) of 34 to fluoxetine and 6 (18%) of 33 to the
placebo ( 21 = 8.8; P=.003).
The BDD symptoms of delusional patients were as likely as those of nondelusional
patients to respond to fluoxetine, and no delusional patients responded to
the placebo. In the sample as a whole, treatment response was independent
of the duration and severity of BDD and the presence of major depression,
obsessive-compulsive disorder, or a personality disorder. Fluoxetine was generally
well tolerated.
Conclusion Fluoxetine is safe and more effective than placebo in delusional and
nondelusional patients with BDD.
From Butler Hospital and the Department of Psychiatry and Human Behavior,
Brown University School of Medicine, Providence, RI. Dr Phillips has received
research support and occasional speaking honoraria from Eli Lilly & Co,
Indianapolis, Ind.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati
What's this?
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
Intensive Cognitive-Behavioral Therapy for Adolescents With Body Dysmorphic Disorder
Aldea et al.
Clinical Case Studies 2009;8:113-121.
ABSTRACT
Body Dysmorphic Disorder: Treating an Underrecognized Disorder
Phillips et al.
Am. J. Psychiatry 2008;165:1111-1118.
FULL TEXT
Efficacy of Treatment for Somatoform Disorders: A Review of Randomized Controlled Trials
Kroenke
Psychosom. Med. 2007;69:881-888.
ABSTRACT
| FULL TEXT
A 12-Month Follow-Up Study of the Course of Body Dysmorphic Disorder
Phillips et al.
Am. J. Psychiatry 2006;163:907-912.
ABSTRACT
| FULL TEXT
Clinical Features and Treatment of Body Dysmorphic Disorder
Phillips
Focus 2005;3:179-183.
ABSTRACT
| FULL TEXT
Placebo-Controlled Study of Pimozide Augmentation of Fluoxetine in Body Dysmorphic Disorder
Phillips
Am. J. Psychiatry 2005;162:377-379.
ABSTRACT
| FULL TEXT
Change in Psychosocial Functioning and Quality of Life of Patients With Body Dysmorphic Disorder Treated With Fluoxetine: A Placebo-Controlled Study
Phillips and Rasmussen
Psychosomatics 2004;45:438-444.
ABSTRACT
| FULL TEXT
Treatment of Somatoform Disorders With St. John's Wort: A Randomized, Double-Blind and Placebo-Controlled Trial
Muller et al.
Psychosom. Med. 2004;66:538-547.
ABSTRACT
| FULL TEXT
Body dysmorphic disorder
Veale
Postgrad. Med. J. 2004;80:67-71.
ABSTRACT
| FULL TEXT
Fluoxetine was safe and effective for body dysmorphic disorder
Rao
Evid. Based Ment. Health 2002;5:119-119.
FULL TEXT
Fluoxetine for Body Dysmorphic Disorder
Journal Watch Dermatology 2002;2002:9-9.
FULL TEXT
Treatment for Body Dysmorphic Disorder
JWatch Women's Health 2002;2002:5-5.
FULL TEXT
|
